Loading
WM formula Group / Obesity / Control group · Interventional Study
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed but unpublished registry record for a small, two-arm crossover trial evaluating a multi-component dietary supplement (WM Formula) on GLP-1 secretion and glycemic biomarkers in adults with elevated body fat percentage. Results are not posted on ClinicalTrials.gov; the strength and direction of any effect remain unknown.
Interventional, Randomized, Crossover, Quadruple masking, Prevention purpose. Obesity; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Experimental: WM formula Group. Compared with: No Intervention: Control group — Placebo Comparator. n = 20. 1 site: Taiwan.
This is a completed but unpublished registry record for a small, two-arm crossover trial evaluating a multi-component dietary supplement (WM Formula) on GLP-1 secretion and glycemic biomarkers in adults with elevated body fat percentage. Results are not posted on ClinicalTrials.gov; the strength and direction of any effect remain unknown.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Until results are published, no clinical inference can be drawn. Clinicians should await peer-reviewed findings before considering the WM Formula's efficacy for GLP-1 secretion or glycemic control.
This is a completed but unpublished registry record for a small dietary supplement study with surrogate endpoints; results are not reported in this record.
As stated by the source record.
Quoted from the source exactly as published.
Until results are published, no clinical inference can be drawn. Clinicians should await peer-reviewed findings before considering the WM Formula's efficacy for GLP-1 secretion or glycemic control.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07097987). This is a study registration, not published results. Lead sponsor: TCI Co., Ltd.. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 20 participants (ACTUAL). Conditions: Obesity. Interventions: DIETARY_SUPPLEMENT: WM formula Group; DIETARY_SUPPLEMENT: Control group. Primary outcome measures: Plasma GLP-1 concentration (pmol/L) , Day 1 and Day 7; Blood glucose concentration (mg/dL) , Day 1 and Day 7; Serum insulin concentration (μIU/mL) , Day 1 and Day 7; Plasma DPP-4 concentration (ng/mL) , Day 1 and Day 7. Brief summary: The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage. The WM Formula is a multi-component dietary supplement composed of Bifidobacterium breve (Active), Rocket Apple Extract Powder (Active), Probio-kombu Black Tea Powder (Active), Soy Protein (Excipient), Gum Acacia (Excipient), and Erythritol (Excipient). Participants enrolled in the study will be required to undergo blood collection, height measurement, body composition analysis, and questionnaire completion. Each testing session will take approximately 5 hours, and participants will need to complete two trial visits in total. There will be a 7-day washout period between the two trial sessions (i.e., after completion of the first trial, the second trial will be scheduled at least 7 days later). On each trial day, blood samples and relevant assessments will be conducted at the following time points: before ingestion of the test product or placebo, and at 15, 30, 45, 60, 90, 120, and 240 minutes post-ingestion.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.